Evidence map›Paper›PMID 21251657›Full record

ArticleJournal of biomechanics2011

TGF-β1 diminishes collagen production during long-term cyclic stretching of engineered connective tissue: implication of decreased ERK signaling.

Zeeshan H Syedain, Robert T Tranquillo

Open access · greenAbstract read
In one paragraph

Article in Journal of biomechanics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Frontiers in cardiovascular medicine · 2019
    Article
  8. Article
  9. Review
  10. TGFβ signaling promotes matrix assembly during mechanosensitive embryonic salivary gland restoration.Matrix biology : journal of the International Society for Matrix Biology · 2015
    Article
  11. Article
  12. Influence of mechanical stimulation on human dermal fibroblasts derived from different body sites.International journal of clinical and experimental medicine · 2015
    Article
  13. Article
  14. Tubular heart valves from decellularized engineered tissue.Annals of biomedical engineering · 2013
    Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Zeeshan H SyedainDepartment of Chemical Engineering & Materials Science, University of Minnesota, MN 55455, USA.
Robert T Tranquillo
University of Minnesota · US

Funding

Tissue-engineering Valve from Cell-Remodeled BiopolymerR01HL071538 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI TRANQUILLO, ROBERT T · 2003 to 2007
$4.1M
Engineered Artery Growth in Vitro, Cell-Remodeled FibrinR01HL083880 · NHLBI · UNIVERSITY OF MINNESOTA · PI TRANQUILLO, ROBERT T · 2006 to 2010
$3.9M
NHLBI NIH HHS BRP HL71538NHLBI NIH HHS R01 HL071538NHLBI NIH HHS R01 HL083880
6 · The paper itself

Abstract

Cyclic stretching and growth factors like TGF-β have been used to enhance extracellular matrix (ECM) production by cells in engineered tissue to achieve requisite mechanical properties. In this study, the effects of TGF-β1 were evaluated during long-term cyclic stretching of fibrin-based tubular constructs seeded with neonatal human dermal fibroblasts. Samples were evaluated at 2, 5, and 7 weeks for tensile mechanical properties and ECM deposition. At 2 weeks, +TGF-β1 samples had 101% higher collagen concentration but no difference in ultimate tensile strength (UTS) or modulus compared to -TGF-β1 samples. However, at weeks 5 and 7, -TGF-β1 samples had higher UTS/modulus and collagen concentration, but lower elastin concentration compared to +TGF-β1 samples. The collagen was better organized in -TGF-β1 samples based on picrosirius red staining. Western blot analysis at weeks 5 and 7 showed increased phosphorylation of ERK in -TGF-β1 samples, which correlated with higher collagen deposition. The TGF-β1 effects were further evaluated by western blot for αSMA and SMAD2/3 expression, which were 16-fold and 10-fold higher in +TGF-β1 samples, respectively. The role of TGF-β1 activated p38 in inhibiting phosphorylation of ERK was evaluated by treating samples with SB203580, an inhibitor of p38 activation. SB203580-treated cells showed increased phosphorylation of ERK after 1 hour of stretching and increased collagen production after 1 week of stretching, demonstrating an inhibitory role of activated p38 via TGF-β1 signaling during cyclic stretching. One advantage of TGF-β1 treatment was the 4-fold higher elastin deposition in samples at 7 weeks. Further cyclic stretching experiments were thus conducted with constructs cultured for 5 weeks without TGF-β1 to obtain improved tensile properties followed by TGF-β1 supplementation for 2 weeks to obtain increased elastin content, which correlated with a reduction in loss of pre-stress during preconditioning for tensile testing, indicating functional elastin. This study shows that a sequential stimulus approach - cyclic stretching with delayed TGF-β1 supplementation - can be used to engineer tissue with desirable tensile and elastic properties.

Indexed as

Azo CompoundsCollagenConnective TissueElasticityEnzyme InhibitorsExtracellular Signal-Regulated MAP KinasesFibroblastsHumansInfant, Newbornp38 Mitogen-Activated Protein KinasesSignal TransductionSkinStress, MechanicalTensile StrengthTissue EngineeringTransforming Growth Factor beta1Azo CompoundsC.I. direct red 80CollagenEnzyme InhibitorsExtracellular Signal-Regulated MAP Kinasesp38 Mitogen-Activated Protein KinasesTransforming Growth Factor beta1

Identifiers

PMID21251657
PMCPMC3061833
OpenAlexW2081146929

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.